Navigation Links
Health and Environmental Groups Announce Intent to Sue Illinois Coal Plant Owners for Violating Clean Air Act
Date:7/28/2009

f of individuals and families affected by lung cancer, asthma, COPD (chronic bronchitis and emphysema), and other lung diseases. www.lungchicago.org

The Sierra Club is the nation's oldest and largest grassroots environmental organization. Its Beyond Coal Campaign is working to retire old coal plants that are the worst contributors to health-harming soot and smog pollution and replace them with clean energy solutions. www.sierraclub.org/coal


'/>"/>
SOURCE Environmental Law & Policy Center
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Cardinal Health Announced as Title Sponsor of the Health Connect Partners 2009 Fall Hospital Pharmacy Conference
2. Patients With Bipolar Disorder at Increased Risk for Wide Range of Health Problems, Thomson Reuters Study Finds
3. Clear Choice Health Plans Selects Thomson Reuters to Deliver Healthcare Cost Information to Members - and Exceed State Transparency Requirements
4. Nexicon Technology to Protect Healthcare Industry
5. CA Representative Elected to Continua Health Alliance Board of Directors
6. Resvera Health Rx Launches All-Natural Resveratrol-Based Supplement with Anti-Aging and Disease-Fighting Properties
7. URAC Launches New eLearning Courses for Health Care Management Accreditation
8. Houston Northwest Medical Centers Bariatric Program Rated Top 15% in the Nation by HealthGrades
9. Genomic Health to Announce Second Quarter 2009 Financial Results and Host Conference Call on Tuesday, August 4, 2009
10. Employers See Well-Designed Worksite Health and Wellness Programs as Strong Value in Down Economy
11. Ecigarettesnational.com Says Claim by FDA and Other Health Organizations Intentionally Misleading
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/21/2014)... York, NY (PRWEB) December 21, 2014 ... nearing 1,400 in a consolidated litigation underway in New ... documents, a total of 1,375 claims involving the birth ... Superior Court. These lawsuits were filed by women who ... to have led to uterine perforations and other complications ...
(Date:12/21/2014)... 21, 2014 Parker & Sons, Inc. ... cooling, plumbing and other similar home contractor services announces ... regard to its expert contracting services. The company is ... has been serving Arizona for well over 40 years. ... absolute best in quality customer service to the residents ...
(Date:12/21/2014)... Viejo, California (PRWEB) December 21, 2014 ... Studios have announced a new intro plugin for Final ... to animate pictures, videos, logos, and more with absolute ... “We’ve given our users the tools needed to easily ... ProMotion allows Final Cut Pro X users to animate ...
(Date:12/21/2014)... The Oncology Institute of Hope and Innovation ... and Whittier offices. The Hope for the Holidays Toy Drive ... and their families during the holiday season. This year, the ... children between both offices. This event continues to be successful ... service team, store managers and assistant managers came out and ...
(Date:12/20/2014)... BambooIndustry.com is a leading eco-friendly bamboo flooring ... bamboo flooring promotion for the coming 2015. , ... and offers the best bamboo products and services ... all customers can enjoy a special discount, up ... BambooIndustry.com from press releases. , The bamboo flooring ...
Breaking Medicine News(10 mins):Health News:Mirena Lawsuits Approach 1,400 in Bergen County Litigation, Bernstein Liebhard LLP Reports 2Health News:Mirena Lawsuits Approach 1,400 in Bergen County Litigation, Bernstein Liebhard LLP Reports 3Health News:Parker & Sons Announces Record Number Of Favorable Reviews In 2014 With Regard To Its Expert Contracting Services 2Health News:Parker & Sons Announces Record Number Of Favorable Reviews In 2014 With Regard To Its Expert Contracting Services 3Health News:Announcing a new plugin for Final Cut Pro X ProMotion from Pixel Film Studios. 2Health News:Eco-friendy Bamboo Flooring Manufacturer BambooIndustry.com Introduces Its Bamboo Flooring Promotion for 2015 2
... of ... Hematology 2007, SINGAPORE, Dec. ... most advanced compounds at The American Society of,Hematology 49th Annual Meeting ... and selective JAK2 inhibitor SB1518,highlighted the therapeutic potential of SB1518 for ...
... SAN JOSE, Calif., Dec. 10 Human Pheromone ... Company") today announced,today that its Board of Directors ... of common stock, representing approximately 10% of the,current ... open market and,private transactions. The plan sets no ...
... 90 mg, * 53% of Patients Treated with 90 mg ... Reduction in the Risk of Death ... Compared to Non-responders, ATLANTA, Dec. 10 ... maturing data,from the Phase 1/2 study investigating the combined use of MGCD0103, ...
... (Nasdaq: MLNM ) today reported the presentation ... III clinical trial, comparing,VELCADE and dexamethasone (VcD) to ... by the Intergroupe,Francophone du Myelome (IFM) cooperative group ... at the American Society of Hematology (ASH) 49th,Annual ...
... Calls to Quitline, EAGAN, Minn., Dec. 10 ... of Minnesota (Blue Cross), recorded that more of,its members ... enrollment,data reported by Blue Cross, telephone coaching quitline. Stop-smoking,quitline ... in October,2007 -- nearly a 43 percent increase. This ...
... the past 30 years,the San Antonio Breast Cancer ... among scientists and clinicians from around the world, ... providing an ideal format for,scientists to present, for ... as,well as other pertinent information, including diagnostic developments., ...
Cached Medicine News:Health News:S*BIO's Oral JAK2 Inhibitor SB1518 Demonstrates Therapeutic Potential for the Treatment of Myeloproliferative and Other Hematological Disorders 2Health News:S*BIO's Oral JAK2 Inhibitor SB1518 Demonstrates Therapeutic Potential for the Treatment of Myeloproliferative and Other Hematological Disorders 3Health News:Human Pheromone Sciences Announces Stock Repurchase Program 2Health News:Pharmion and MethylGene Present Favorable Clinical Data From Combination MGCD0103/Vidaza(R) Study in Myelodysplastic Syndromes and Acute Myelogenous Leukemia at The 49th American Society of Hematology (ASH) Meeting 2Health News:Pharmion and MethylGene Present Favorable Clinical Data From Combination MGCD0103/Vidaza(R) Study in Myelodysplastic Syndromes and Acute Myelogenous Leukemia at The 49th American Society of Hematology (ASH) Meeting 3Health News:Pharmion and MethylGene Present Favorable Clinical Data From Combination MGCD0103/Vidaza(R) Study in Myelodysplastic Syndromes and Acute Myelogenous Leukemia at The 49th American Society of Hematology (ASH) Meeting 4Health News:Pharmion and MethylGene Present Favorable Clinical Data From Combination MGCD0103/Vidaza(R) Study in Myelodysplastic Syndromes and Acute Myelogenous Leukemia at The 49th American Society of Hematology (ASH) Meeting 5Health News:Pharmion and MethylGene Present Favorable Clinical Data From Combination MGCD0103/Vidaza(R) Study in Myelodysplastic Syndromes and Acute Myelogenous Leukemia at The 49th American Society of Hematology (ASH) Meeting 6Health News:Pharmion and MethylGene Present Favorable Clinical Data From Combination MGCD0103/Vidaza(R) Study in Myelodysplastic Syndromes and Acute Myelogenous Leukemia at The 49th American Society of Hematology (ASH) Meeting 7Health News:VELCADE(R) (Bortezomib) for Injection Based Therapy Produced Significant Complete Remission Rates Pre- and Post-Transplantation in IFM Phase III Front-Line Multiple Myeloma Trial 2Health News:VELCADE(R) (Bortezomib) for Injection Based Therapy Produced Significant Complete Remission Rates Pre- and Post-Transplantation in IFM Phase III Front-Line Multiple Myeloma Trial 3Health News:VELCADE(R) (Bortezomib) for Injection Based Therapy Produced Significant Complete Remission Rates Pre- and Post-Transplantation in IFM Phase III Front-Line Multiple Myeloma Trial 4Health News:VELCADE(R) (Bortezomib) for Injection Based Therapy Produced Significant Complete Remission Rates Pre- and Post-Transplantation in IFM Phase III Front-Line Multiple Myeloma Trial 5Health News:VELCADE(R) (Bortezomib) for Injection Based Therapy Produced Significant Complete Remission Rates Pre- and Post-Transplantation in IFM Phase III Front-Line Multiple Myeloma Trial 6Health News:Blue Cross' Stop Smoking Phone Coaching Enrollments Jumped in October 2Health News:San Antonio Breast Cancer Symposium December 13th to 16th 2007 2
(Date:12/19/2014)... WORTH, Texas , December 18, 2014 /PRNewswire/ ... a networked software application/module that is used to ... related images. RIS comprises a patient tracking and ... system. The integration of RIS with HIS and ... used for patient registration and patient scheduling, patient ...
(Date:12/19/2014)... REDWOOD CITY, Calif., Dec. 18, 2014 ... on the development of medical diagnostics based on ... of gas flow, today announced financial results for ... 30, 2014. "Following the completion of ... well positioned to maximize the recently initiated CoSense® ...
(Date:12/19/2014)... , Dec. 19, 2014  Eli Lilly and ... Paris: FR0011184241 – ADOC) today announced a worldwide licensing ... BioChaperone Lispro, for treatment in people with type 1 ... proprietary BioChaperone® technology and is currently in Phase Ib ... Lispro with the goal of optimizing glucose levels during ...
Breaking Medicine Technology:The Global Radiology Information Systems Market is Expected to Grow at a CAGR of 7.5% from 2014 to 2019 2The Global Radiology Information Systems Market is Expected to Grow at a CAGR of 7.5% from 2014 to 2019 3Capnia Reports Third Quarter 2014 Financial Results 2Capnia Reports Third Quarter 2014 Financial Results 3Capnia Reports Third Quarter 2014 Financial Results 4Capnia Reports Third Quarter 2014 Financial Results 5Capnia Reports Third Quarter 2014 Financial Results 6Capnia Reports Third Quarter 2014 Financial Results 7Capnia Reports Third Quarter 2014 Financial Results 8Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 2Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 3
... , MORRISTOWN, N.J. , May 24 Watson ... subsidiary, Watson Laboratories, Inc., has received approval from the United States ... for Valacyclovir Hydrochloride tablets, USP, in the 500 and 1000 mg ... to begin shipping the product shortly.   , ...
... Genzyme Corp. has signed a consent decree agreeing to correct manufacturing quality violations at ... government $175 million in unlawful profits from the sale of products that ... , , ... , , ...
Cached Medicine Technology:Watson's Generic VALTREX® 500 mg and 1000 mg Receives FDA Approval 2Watson's Generic VALTREX® 500 mg and 1000 mg Receives FDA Approval 3Genzyme Corp. Signs Consent Decree to Correct Violations at Allston, Mass., Manufacturing Plant and Give up $175 Million in Profits 2Genzyme Corp. Signs Consent Decree to Correct Violations at Allston, Mass., Manufacturing Plant and Give up $175 Million in Profits 3
BD Vacutainer® Specialty Tubes - Trace Element - Plastic...
Inquire...
VACUETTE paediatric tubes have decreased sample volumes and are ideal for small childrens' veins and geriatric patients....
BD Vacutainer® Plus Plastic Serum Tubes have spray-coated silica and are used for serum determinations in chemistry, serology, and immunohematology....
Medicine Products: